News >

Monitoring in CML Remains Imperative as TKI Cessation Rises to the Forefront of Care

Caroline Seymour
Published: Wednesday, Jul 03, 2019

Vivian G. Oehler, MD

Vivian G. Oehler, MD

Even if a patient with chronic myeloid leukemia (CML) qualifies for tyrosine kinase inhibitor (TKI) discontinuation, it does not mean they are out of the woods, explained Vivian G. Oehler, MD, adding that monitoring becomes even more important in this context.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication